Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials
China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and...
Degron Therapeutics
Degron Therapeutics Secures $20M Series A+ for Molecular Glue Drug Development
China-based Degron Therapeutics, a specialist in molecular glue-based drugs, has reportedly raised over USD 20...
Degron Therapeutics Partners with Takeda for Molecular Glue Degraders Development
Degron Therapeutics, a biopharmaceutical company based in China, has entered into a collaboration development and...